Stockreport

Soleno Therapeutics Announces Positive Outcome from Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome

Soleno Therapeutics, Inc.  (SLNO) 
Last soleno therapeutics, inc. earnings: 5/13 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.soleno.life/investor-overview
PDF REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics [Read more]